Navepdekinra

Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis.


Cat. No.: EX-A12813	Purity: >98%

	Chemical structure of Navepdekinra

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2467732-66-5
Purity	>98%
Formula	C33H48FN7O4
Mol Weight	625.7771
Color	white
State	Solid
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Paul R. Fatheree, et al. IL-17 Ligands And Uses Thereof. US20200247785A1. [2]. Kim D, et al. Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. Am J Clin Dermatol. 2025 May;26(3):307-320. [3]. Xiaobing Deng, et al. The Critical and Unexpected Role of a Methyl Group in Interleukin-17A Inhibitors. bioRxiv 2025.10.02.680113
CoA	CoA of Navepdekinra

Smiles:	O=C(C1=CC=NN1CC)N[C@@H]([C@@]2([H])CC[C@@H](CC2)C)C(NC3=C(C=C(C=C3)[C@H](C)[C@@H](NC(CC)=O)C(N4CCN(CC4)C)=O)F)=O


		Search